March 20, 2018 / 12:12 PM / a month ago

BRIEF-Kalytera Initiates Program To Develop A Novel Cannabinoid-Based Compound For Treatment Of Acute And Chronic Pain

March 20 (Reuters) - Kalytera Therapeutics Inc:

* KALYTERA INITIATES PROGRAM TO DEVELOP A NOVEL CANNABINOID-BASED COMPOUND FOR TREATMENT OF ACUTE AND CHRONIC PAIN

* KALYTERA THERAPEUTICS INC - ‍KALYTERA OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FOR COMPOUND FROM BEETLEBUNG PHARMA, LTD​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below